The BioSig Tech PURE EP System Aims for Arrhythmia Market

After nearly a decade of research and development, BioSig Tech could be poised to break into the nearly $5 billion global electrophysiology market.

In the spring of 2018, the West Los Angeles-based medical device company has filed for federal approval for a medical device that can help doctors target the cells that cause arrhythmias, or irregular heartbeats, which increase the risks of cardiac problems and stroke.

This biomedical device, called PURE EP, aims to cut through the background noise of the operating room and its equipment in order to allow doctors to pinpoint parts of the heart that cause atrial fibrillation and ventricular tachycardia.

The heart’s bioelectronic signals are displayed on monitors as clearly defined graphs by the PURE EP System. These signals can be quickly and easily understood by doctors, so they don’t have to stop and review the signals for the accuracy or filter them.

The BioSig Tech system removes all interference and artifact. This system presents clear information to the surgeons, to help guide their procedures.

Nearly 34 million people worldwide are affected by atrial fibrillation, the most common arrhythmia, including 6.1 million in the U.S.

The $4.6 billion global market for electrophysiology is expected to reach $8.3 billion by 2022. 

Precise treatment

BioSig Tech’s PURE EP device is a biomedical signal processing platform. It helps cardiologists perform catheter ablation, a procedure that can lessen arrhythmias.

This system has the goal to decipher the high-frequency signals used by doctors to discover which abnormal electrical pathways in the heart have caused an irregular heartbeat.

After the offending tissue was “burn” with radiofrequency energy, the Pure EP can tell doctors whether they were successful or not. The number of subsequent procedures can be reduced by more accurate targeting.

BioSig Tech is taking signal processing that’s been around for many years and is applying it to electrophysiology. BioSig Tech is giving them the precise information that they never had before.

The shares of this company trade over the counter. This company is pre-revenue. It has posted a loss of $12.8 million last year and has raised $35 million in funding, including $3.5 million from its founder Kenneth Londoner.

BioSig Tech has 19 employees in Los Angeles, and an administrative office in Austin, Texas.